NCT03686332View on ClinicalTrials.gov

PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 25, 2018

Primary Completion Date

September 28, 2022

Study Completion Date

September 15, 2023

Conditions
Penile Cancer
Interventions
DRUG

Arm A: Atezolizumab and Radiotherapy

patients will receive atezolizumab, 1200 mg, every 3 weeks, by IV infusion. Patients in group A will additionally receive 33 fractions of 1.5 (locoregional affected lymph nodes) and 1.8 Gy (tumor+margin) irradiation, concurrently with atezolizumab treatment.

DRUG

Arm B: Atezolizumab

patients will receive atezolizumab, 1200 mg, every 3 weeks, by IV infusion.

Trial Locations (1)

1066 CX

Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER

NCT03686332 - PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study | Biotech Hunter | Biotech Hunter